Vutrisiran Sodium Kit (25mg 0.5ml/syringe) 15syringes,and 78 other contracts

2026-11-03

Official in charge of disbursement of the procuring entity : Tatsuo Ushiki, President, National University Corporation Niigata University Classification of the products to be procured : Nature and quantity of the products to be purchased : A Vutrisiran Sodium Kit (25mg 0.5ml/syringe) 15syringes B Cipaglucosidase Alfa (Genetical Recombination) 325vials C Privigen 10% I.V. Injection (20g/200mL) 160vials D Pembrolizumab (Genetical Recombination) (100mg 4ml/vial) 2,830vials E Letermovir (240mg 14tablets/case) 290cases F Letermovir (240mg 12mL/vial) 140boxes G Sotatercept (Genetical Recombination) (45mg/vial) 20vials H Enfortumab Vedotin (Genetical Recombination) (20mg/vial) 395vials I Zolbetuximab (Genetical Recombination) (100mg/vial) 365vials J Durvalumab (Genetical Recombination) (500mg 10ml/vial) 1,420vials K Osimertinib Mesilate (80mg/tablet, 14tablets/boxes) 140boxes L Benralizumab (Genetical Recombination) (30mg 1mL/kit) 95kits M Benralizumab (Genetical Recombination) (30mg 1ml/syringe) 95syringes N Anifrolumab (Genetical Recombination) (300mg 2mL/vial) 300vials O Fulvestrant (250mg/syringe, 2syringes/box) 270boxes P Risankizumab (Genetical Recombination) (150mg 1mL/syringes) 90syringes Q Risankizumab (Genetical Recombination) (360mg 2.4mL 1KT 1KT) 80kits R Adalimumab (Genetical Recombination) (40mg 0.4mL/syringe) 445syringes Teprotumumab (Genetical Recombination) (500mg/vial) 30vials T Ravulizumab (Genetical Recombination) (300mg 3ml/vial) 675vials U Eculizumab (Genetical Recombination) (300mg 30mL/vial) 105vials V ARIKAYCE (amikacin liposome inhalation suspension) (590mg/8.4mL) 235boxes W Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets/vial) 365boxes X Axicabtagene ciloleucel 2sets Y Mepolizumab (Genetical Recombination) (100mg 1ml/kit) 345kits Z Imiglucerase (Genetical Recombination) (400units/vial) 225vials AA Sutimlimab (Genetical Recombination) (1.1g 22mL/vial) 210vials AB Nirsevimab (Genetical Recombination) (100mg 1mL/syringe) 40syringes AC Nirsevimab (Genetical Recombination) (50mg 0.5mL/syringe) 50syringes AD Epcoritamab (Genetical Recombination) (48mg 0.8mL/vial) 15vials AE Clazosentan Sodium (150mg 6mL/vial) 30boxes AF Canakinumab (Genetical Recombination) (150mg 1ml/vial) 55vials AG Tisagenlecleucel 2sets AH Nusinersen Sodium (12mg 5ml/vial) 3vials AI Galsulfase (Genetical Recombination) (5mg 5mL/vial) 200vials AJ Methotrexate (1,000㎎ 40mL/vial) 725vials AK Ipilimumab (Genetical Recombination) (50mg 10ml/vial) 130vials AL Revlimid Capsules (5mg/capsule) 120boxes AM Abatacept (Genetical Recombination) (250mg 1/vial) 475vials AN Cetuximab (Genetical Recombination) (100mg 20ml/vial) 2,410vials AO Avelumab (Genetical Recombination) (200mg 10ml/vial) 235vials AP Daratumumab (Genetical Recombination) Vorhyaluronidase Alfa (Genetical Recombination) (15mL/vial) 80vials AQ Daratumumab (Genetical Recombination) (400mg 20ml/vial) 160vials AR Romiplostim (Genetical Recombination) (250㎍/vial) 725vials A Burosumab (Genetical Recombination) (30mg 1ml/vial) 45vials AT Mogamulizumab (Genetical Recombination) (20mg 5mL/vial) 220vials AU Pegfilgrastim (Genetical Recombination) (3.6mg 0.36ml/syringe) 400syringes AV Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL/kit) 265kits AW Aflibercept (Genetical Recombination) (2mg 0.05ml/syringe) 405syringes AX Agalsidase Beta B I.V. Infusion 35mg [JCR] (35mg/vial) 165vials AY Agalsidase Beta (Genetical Recombination) (5mg/vial) 275vials AZ Nivolumab (Genetical Recombination) (240mg 24ml/vial) 910vials BA Nivolumab (Genetical Recombination) (240mg 24mL/vial) 170vials BB Paclitaxel (100mg/vial) 1,160vials BC Trastuzumab Deruxtecan (Genetical Recombination) (100mg/vial) 465vials BD Denosumab (Genetical Recombination) (120mg 1mL 1/syringe) 1,175syringes BE Denosumab (Genetical Recombination) (120mg 1.7ml/vial) 1,175vials BF Atezolizumab (Genetical Recombination) (1,200mg 20ml/vial) 390vials BG Bevacizumab (Genetical Recombination) (400mg 16ml/vial) 480vials BH PHESGO Combination for Subcutaneous Injection (10mL/vial) 140vials BI Tocilizumab (Genetical Recombination) (200mg 10ml/vial) 1,440vials BJ Tocilizumab (Genetical Recombination) (162mg 0.9ml/kit) 950cases BK Trastuzumab Emtansine (Genetical Recombination) 120vials BL Crovalimab (Genetical Recombination) (100mg/vial) 15vials BM Trastuzumab emtansine (Genetical Recombination) (160mg/vial) 60vials BN Pertuzumab (Genetical Recombination) (420mg 14ml/vial) 95vials BO Lanreotide Acetate (120mg/syringe) 185syringes BP Ustekinumab (Genetical Recombination) (45mg 0.5ml/syringe) 650syringes BQ Infliximab (Genetical Recombination) (100mg/vial) 1,715vials BR Inebilizumab (Genetical Recombination) (100mg 10mL/vial, 3vials/box) 3boxes B Ganciclovir (500mg/vial) 1,945vials BT Ramucirumab (Genetical Recombination) (500mg 50ml/vial) 100vials BU Selpercatinib (80mg/CA, 56CA/box) 80boxes BV Infliximab B for I.V. Infusion 100mg "NK" (100mg/vial) 2,380vials BW Polyethylene glycol treated human normal immunoglobulin (10g 100ml/vial) 640vials BX Daunorubicin Hydrochloride Cytarabine (144mg/vial) 55vials BY Daunorubicin Hydrochloride (5g 100mL/vial) 810vials BZ Cytarabine (100mg 5mL/vial) 520vials CA Brentuximab Vedotin (Genetical Recombination) (50mg/vial) 70vials Delivery period : From April, 202 through 3 March, 202 Delivery place : Niigata University Medical and Dental Hospital Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article over the past one year and Article of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorshi or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause, B have the Grade A or Grade B qualification during fiscal 202 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency, C prove to have obtained license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University, E meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article of the Regulation, F not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University. Time limit of tender : 1 : 1 1 March, 202 Contact point for the notice : Yuji Kaido, Procurement Section, Niigata University Medical and Dental Hospital, 75 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951-852 Japan, TEL 025-227-243 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

Japan

2026-03-26